SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19

被引:13
作者
Liang, Hong-Yu [1 ]
Wu, Yuyan [2 ,3 ]
Yau, Vicky [4 ]
Yin, Huan-Xin [1 ]
Lowe, Scott [5 ]
Bentley, Rachel [5 ]
Ahmed, Mubashir Ayaz [6 ]
Zhao, Wenjing [7 ]
Sun, Chenyu [7 ]
机构
[1] Anhui Med Univ, Sch Clin Med 2, Hefei 230032, Peoples R China
[2] First Peoples Hosp Hefei, 390 N Huaihe Rd, Hefei 230061, Peoples R China
[3] Philippine Womens Univ, Sch Nursing, 1743 Taft Ave, Manila 1004, Philippines
[4] Columbia Univ, Div Oral & Maxillofacial Surg, Irving Med Ctr, 622W 168th St, New York, NY 10032 USA
[5] Kansas City Univ, Coll Osteopath Med, 1750 Independence Ave, Kansas City, MO 64106 USA
[6] AMITA Hlth St Joseph Hosp Chicago, 2900 N Lake Shore Dr, Chicago, IL 60657 USA
[7] Yangzhou Univ, Northern Jiangsu Peoples Hosp, Nantong Western Rd 98, Yangzhou 225000, Jiangsu, Peoples R China
关键词
COVID-19; SARS-CoV-2; variants; vaccines; molecular therapeutic target; RECEPTOR-BINDING DOMAIN; DELTA VARIANT; MUTATIONS; ESCAPE; SPIKE; ACE2; NEUTRALIZATION; INFECTION; ANAKINRA; SCOTLAND;
D O I
10.3390/vaccines10091538
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Over the past two years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused hundreds of millions of infections, resulting in an unprecedented pandemic of coronavirus disease 2019 (COVID-19). As the virus spreads through the population, ongoing mutations and adaptations are being discovered. There is now substantial clinical evidence that demonstrates the SARS-CoV-2 variants have stronger transmissibility and higher virulence compared to the wild-type strain of SARS-CoV-2. Hence, development of vaccines against SARS-CoV-2 variants to boost individual immunity has become essential. However, current treatment options are limited for COVID-19 caused by the SARS-CoV-2 variants. In this review, we describe current distribution, variation, biology, and clinical features of COVID-19 caused by SARS-CoV-2 variants (including Alpha (B.1.1.7 Lineage) variant, Beta (B.1.351 Lineage) variant, Gamma (P.1 Lineage) variant, Delta (B.1.617.2 Lineage) variant, and Omicron (B.1.1.529 Lineage) variant and others. In addition, we review currently employed vaccines in clinical or preclinical phases as well as potential targeted therapies in an attempt to provide better preventive and treatment strategies for COVID-19 caused by different SARS-CoV-2 variants.
引用
收藏
页数:27
相关论文
共 206 条
[1]   Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19 [J].
Abd El-Aziz, Tarek Mohamed ;
Al-Sabi, Ahmed ;
Stockand, James D. .
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
[2]   The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern [J].
Abdelnabi, Rana ;
Foo, Caroline S. ;
Jochmans, Dirk ;
Vangeel, Laura ;
De Jonghe, Steven ;
Augustijns, Patrick ;
Mols, Raf ;
Weynand, Birgit ;
Wattanakul, Thanaporn ;
Hoglund, Richard M. ;
Tarning, Joel ;
Mowbray, Charles E. ;
Sjo, Peter ;
Escudie, Fanny ;
Scandale, Ivan ;
Chatelain, Eric ;
Neyts, Johan .
NATURE COMMUNICATIONS, 2022, 13 (01)
[3]   Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses [J].
Abu-Raddad, Laith J. ;
Chemaitelly, Hiam ;
Yassine, Hadi M. ;
Benslimane, Fatiha M. ;
Al Khatib, Hebah A. ;
Tang, Patrick ;
Malek, Joel A. ;
Coyle, Peter ;
Ayoub, Houssein H. ;
Al Kanaani, Zaina ;
Al Kuwari, Einas ;
Jeremijenko, Andrew ;
Kaleeckal, Anvar Hassan ;
Latif, Ali Nizar ;
Shaik, Riyazuddin Mohammad ;
Abdul Rahim, Hanan F. ;
Nasrallah, Gheyath K. ;
Al Kuwari, Mohamed Ghaith ;
Al Romaihi, Hamad Eid ;
Al-Thani, Mohamed H. ;
Al Khal, Abdullatif ;
Butt, Adeel A. ;
Bertollini, Roberto .
JOURNAL OF TRAVEL MEDICINE, 2021, 28 (07)
[4]   Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants [J].
Accorsi, Emma K. ;
Britton, Amadea ;
Fleming-Dutra, Katherine E. ;
Smith, Zachary R. ;
Shang, Nong ;
Derado, Gordana ;
Miller, Joseph ;
Schrag, Stephanie J. ;
Verani, Jennifer R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (07) :639-651
[5]   Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca-Oxford COVID-19 vaccine [J].
Al-Ahmad, Mona ;
Al-Rasheed, Mona ;
Shalaby, Neveen Abo Bakr .
EJHAEM, 2021, 2 (03) :534-536
[6]   Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia [J].
Alex, Ruth ;
Gulam, Shabaz Mohiuddin ;
Kumar, Kiran .
ADVANCES IN VIROLOGY, 2022, 2022
[7]   Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study [J].
Almufty, Hind B. ;
Mohammed, Shinah A. ;
Abdullah, Arshad M. ;
Merza, Muayad A. .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (05)
[8]  
Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]
[9]   Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines [J].
Araf, Yusha ;
Akter, Fariya ;
Tang, Yan-dong ;
Fatemi, Rabeya ;
Parvez, Md Sorwer Alam ;
Zheng, Chunfu ;
Hossain, Md Golzar .
JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (05) :1825-1832
[10]   Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].
Baden, Lindsey R. ;
El Sahly, Hana M. ;
Essink, Brandon ;
Kotloff, Karen ;
Frey, Sharon ;
Novak, Rick ;
Diemert, David ;
Spector, Stephen A. ;
Rouphael, Nadine ;
Creech, C. Buddy ;
McGettigan, John ;
Khetan, Shishir ;
Segall, Nathan ;
Solis, Joel ;
Brosz, Adam ;
Fierro, Carlos ;
Schwartz, Howard ;
Neuzil, Kathleen ;
Corey, Larry ;
Gilbert, Peter ;
Janes, Holly ;
Follmann, Dean ;
Marovich, Mary ;
Mascola, John ;
Polakowski, Laura ;
Ledgerwood, Julie ;
Graham, Barney S. ;
Bennett, Hamilton ;
Pajon, Rolando ;
Knightly, Conor ;
Leav, Brett ;
Deng, Weiping ;
Zhou, Honghong ;
Han, Shu ;
Ivarsson, Melanie ;
Miller, Jacqueline ;
Zaks, Tal .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416